Personalis, Inc.

NASDAQ:PSNL

Medical - Diagnostics & Research

Healthcare
$14.98 +3.44%

+$0.34 today

Market cap
$1.62B
Beta
2.28
P/E (TTM)
-11.0
EPS (TTM)
-$0.92
52W Low $3.84High $12.53

Volume 1.47M

Average 2.31M

PSNL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Personalis, Inc.NASDAQ: PSNL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.55M rose 15.1% year over year, ahead of the -4.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 11.1% from the prior quarter. Over 3 fiscal years it compounded at -21.4% a year.

Context

  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.1% holds above the trailing-twelve-month pace of -4.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.55M+11.1% QoQ
Last fiscal yearDec 2025
$9.43M-11.8% YoY
LTMMar 2026
$9.76M-4.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.1%——
1 year-11.8%——
3-year CAGR-21.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.43M USD
Year-over-year change
-11.8%
4-year CAGR
-10.0%

Stock-Based Compensation vs competitors

How PSNL compares with its peers on the latest reported figures

  • PSNL's LTM Mar 2026 stock-based compensation of $9.76M is the 9th largest of the 10 companies compared; the peer median is $32.2M.
  • Its year-over-year change of -4.5% is the 5th highest of 9, against a peer median of -4.4%.
  • Stock-based compensation amounts to 15.1% of revenue for PSNL, versus a peer median of 7.9%.
PSNL Competitors Peer median
Stock-Based Compensation for PSNL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$381.42M +21.6%+32.5%14.1%
GHGuardant Health, Inc.LTM Sep 2026$210.96M +32.4%+20.6%16.5%
VCYTVeracyte, Inc.LTM Jun 2026$48.51M +20.3%+17.7%8.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$35.7M +95.3%-8.5%7.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$25.54M ——6.4%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
GRALGRAIL, Inc.LTM Jun 2026$5.97M -90.3%-8.4%3.6%
Peer median (excluding PSNL) $32.2M-4.4%+12.2%7.9%

Competitors are the stored peer set for PSNL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.23M)(113.32M)(108.3M)(81.28M)(81.27M)
Depreciation & Amortization6.01M8.43M11.3M10.94M10.05M
Deferred Income Tax2.03M0000
Stock-Based Compensation14.38M19.43M14.05M10.69M9.43M
Change in Working Capital(31.14M)10.61M13.48M(2.59M)(10.19M)
Accounts Receivables(12.12M)1.83M(1.09M)9.59M(8.06M)
Inventory29K(2.98M)(1.93M)4.43M(204K)
Accounts Payables(1.46M)3.09M5.18M(8.92M)4.55M
Other Working Capital(17.6M)8.68M11.33M(7.68M)(6.48M)
Other Non-Cash Items3.12M4.61M13.21M17.1M(2.96M)
Operating Cash Flow(70.83M)(70.23M)(56.26M)(45.15M)(74.95M)
Capital Expenditures(11.08M)(49.9M)(10.91M)(1.6M)(4.5M)
Acquisitions (Net)48.99M0(24.01M)00
Purchases of Investments(267.13M)(121.49M)(103.95M)(121.71M)(210.17M)
Sales of Investments218.14M223.92M127.96M88M192.11M
Other Investing Activities(48.99M)024.01M242K0
Investing Cash Flow(60.07M)52.54M13.1M(35.07M)(22.57M)
Debt Repayment3.31M(1.1M)174K(1.13M)585K
Common Stock Issued162.26M03.51M97.82M129.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.13M2.47M7.34M17.98M(189K)
Financing Cash Flow169.7M1.37M11.03M114.67M130.34M
Effect of Forex Changes47K(127K)(16K)(22K)6K
Net Change in Cash38.85M(16.46M)(32.14M)34.43M32.83M
Free Cash Flow(81.91M)(120.13M)(67.17M)(46.75M)(79.45M)

Personalis, Inc.

NASDAQ:PSNL

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.